Navigation Links
Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
Date:8/19/2007

Expects To See Substantial Sales Growth Balance of Year

SAN DIEGO, Aug. 17 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), will present at the Noble Financial Equity Conference at 11:30 a.m. EDT on Tuesday, August 21, 2007 at the Charleston Place Hotel in Charleston, South Carolina.

William Spencer, Imagenetix's Chief Executive Officer will provide a 25 minute presentation outlining the science, products, and prospects for the Company. Commenting on the prospects, Mr. Spencer said, "I believe that the imminent publication of our most recent clinical study, for our Celadrin product, will lead to significant growth in our private label and branding business. Our distributor is negotiating with several large multinational companies for sale of the private label products, particularly in the International Market. We expect these sales in addition to our growth in retail sales to generate substantial growth in sales during the balance of the year."

The presentation with streaming video and PowerPoint, will be webcast live on Noble Financial's conference website at http://www.two-007.net. It is recommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access.

About Imagenetix

Based in San Diego, California, Imagenetix, (OTC Bulletin Board: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops, formulates and private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marked globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information, please visit, http://www.imagenetix.net.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed and will periodically file with the Securities Exchange Commission.


'/>"/>
SOURCE Imagenetix, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2019)... N.J. (PRWEB) , ... November ... ... global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... its next-generation cell line development technology, GPEx® Boost. The technology enhances Catalent’s ...
(Date:11/2/2019)... YORK (PRWEB) , ... October 31, 2019 , ... ... been released by pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise ... This new tool allows researchers to quickly uncover relationships between genes, diseases, variants, ...
(Date:10/29/2019)... ... October 29, 2019 , ... Researchers at Sony recently ... CMS-C multispectral imagers , researchers identified people by the image of a small ... imaging, face recognition, fingerprints and vasculature. , The new CMS4 series of ...
(Date:10/22/2019)... ... October 22, 2019 , ... DermBiont, ... its lead program, DBI-001, met its primary safety endpoints, with no application site ... clinical trial for the treatment of interdigital tinea pedis (athlete’s foot). Additionally, the ...
Breaking Biology Technology:
(Date:11/19/2019)... ... November 19, 2019 , ... The inaugural Cell & Gene Therapy Day takes ... The one-day event will be chaired by Dr Aiman Shalabi, VP R&D, Cell and ... , “We are witnessing significant innovation in cell and gene therapies, and we are ...
(Date:11/14/2019)... , ... November 13, 2019 , ... Personalized Stem ... first patients in an FDA approved clinical trial for stem cell treatment of ... formation of the company as a subsidiary of VetStem Biopharma. , In July of ...
(Date:11/12/2019)... (PRWEB) , ... November 12, 2019 , ... ... Cross-Channel Spend Optimizer that improves digital advertising performance up to 25% and reduces ... Advertising, Cross-Channel Spend Optimizer uses advanced multi-touch attribution (MTA) to predict best advertising ...
Breaking Biology News(10 mins):